CLAIMS

WHAT IS CLAIMED IS:

1. A method of treating restless legs syndrome in a patient, comprising administering to said patient in need of treatment a therapeutically effective amount of bupropion or pharmaceutically acceptable salts thereof.

2. The method according to claims 1, wherein bupropion is administered by intravenously, transdermally, or orally.

3. The method according to claims 1, wherein bupropion is administered in the form of tablet, cachet, capsule, troche, dispersion, suspensions, or solutions.

4. The method according to claim 1 wherein bupropion is administered orally.

5. The method according to claim 1 wherein the amount administered is from about 10 mg to about 750 mg.

6. The method according to claim 5 wherein the amount administered is from about 50 mg to about 600 mg.

7. The method according to claim 6 wherein the amount administered is from about 60 mg to about 450 mg.

8. The method according to claim 1 wherein bupropion is administered as the hydrochloride salt.

9. The method according to claim 1 wherein bupropion is administered in a sustained or controlled release formulation.

10. The method according to claim 1 wherein the pharmaceutically acceptable salt of bupropion is (±)-bupropion hydrochloride.

11. The method according to claim 1 wherein the pharmaceutically acceptable salt of bupropion is (±)-bupropion maleate.

12. The method according to claim 1 wherein the bupropion is (-)-bupropion or pharmacologically acceptable salts thereof.

13. The method according to claim 12 wherein the amount of (-)-bapropion or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total amount of bupropion.

14. The method according to claim 12 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (+)-stereoisomer, is administered together with a pharmaceutically acceptable carrier.

15. The method according to claim 12 wherein (-)-bupropion is administered as the hydrochloride salt.

16. The method of claim 1 wherein (-)-bupropion is administered in a sustained or controlled release formulation.

17. Use of bupropion or pharmacologically acceptable salts thereof for the preparation of a medicament useful for treating restless legs syndrome in a patient.

18. The use of claim 17, wherein the compound is (±)-bupropion hydrochloride.

19. The use of claim 17, wherein the compound is (±)-bupropion maleate.

20. The use of claim 17, wherein the compound is (-)-bupropion or pharmacologically acceptable salts thereof.